The human immunodeficiency virus-infected traveler.
As the number of travelers from industrialized countries who are infected with human immunodeficiency virus (HIV) increases as a consequence of the clinical benefits of highly active antiretroviral therapy (HAART), updated prophylactic knowledge is needed. Vaccine prophylaxis must balance the safety and immunogenicity of vaccines with the estimated risk of acquiring the disease. Further research is needed on antimalarial chemoprophylaxis for travelers who are HAART recipients, because of possible pharmacokinetic interactions. Safe sex practices must be adopted to avoid both spreading of the infection in the host country and superinfection with different HIV strains. Most individuals infected with HIV may travel safely, even though the infectious risk has been reported to be higher for patients with advanced infections than for the general population. These patients are also less likely to produce an effective immune response to vaccines. Migrants and refugees from poor countries are also at risk of acquiring HIV infection. Their legal-residency status may often prevent their access to adequate health services, thus necessitating urgent public health actions.
Castelli
F
F
Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy. castelli@master.cci.unibs.it
Patroni
A
A
D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000009:adverse effects; D003140:Communicable Disease Control; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016867:Immunocompromised Host; D021841:Safe Sex; D014195:Travel; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects
D019380:Anti-HIV Agents; D001428:Bacterial Vaccines; D014765:Viral Vaccines